Information + Taking Control = Best Outcome is the theme running throughout this short, superbly illustrated workbook. Designed to help patients equip themselves with the best information about metastatic prostate cancer, it covers: • how prostate disease spreads and where it can spread to • a summary of diagnostic tests with detailed explanations to aid understanding of PSA levels, staging and Gleason score • all the hormone treatment options and their side effects • what to expect from the disease itself • how to manage key symptoms such as bone pain, urinary problems and fatigue • the treatment options when hormone treatment stops working • useful advice on diet, exercise, and getting the right support • a frank discussion of end of life care • a concise overview of the latest research in this area. With FastTests to test patients' understanding of their condition, handy checklists and plenty of space for patients and their doctors, nurses and family to write notes, this concise, easy-to-read resource will help patients get organized so that they are better equipped to ask the right questions and have more meaningful discussions about their treatment. Ultimately, it will help them make the best decisions about their care. Contents: • Information + Taking Control = Best Outcome • What is metastatic prostate cancer? • What do my test results mean? • Why is my cancer staged? • How will the disease affect me? • How is metastatic prostate cancer treated? • What is available after hormone therapy? • What are the side effects of hormone treatment? • What can I do to help myself? • Monitoring the effects of therapy • Treatment when myeloma returns • End of life care • What is the latest research in this area? • Useful resources

This is the tenth edition of this Fast Facts handbook since the first was published in 1996 – the many iterations are testament to the rapid changes in the field and steadily improving outlook for patients. This new edition introduces the Gleason grade grouping (Chapter 1), which has important prognostic value, and nomograms that are used to evaluate risk (Chapter 3). Our understanding of the genetics and underlying pathogenesis of prostate cancer is growing apace, leading to the identification of germline mutations and the development of genomic tests to help identify and direct therapy for those at greatest risk of developing clinically significant disease. They also provide reassurance for those patients who have opted for active surveillance (Chapters 3 and 5). Imaging techniques are also improving rapidly, particularly multiparametric MRI (Chapter 4). As this book is concise, fully up to date and evidence based, we believe it is an ideal resource for those general urologists, primary care providers, specialist nurses, trainees and allied healthcare professionals who want to get quickly up to speed in this fast-moving and ever-expanding field. Contents: • Epidemiology and pathophysiology • Diet, lifestyle and chemoprevention • Screening and early detection • Diagnosis, staging and prognostic indicators • Management of clinically localized disease • Managing recurrence after initial therapy • Managing metastatic hormone-sensitive prostate cancer • Management of castrate-resistant prostate cancer • Survivorship and management of treatment-related side effects and complications

Prostate cancer is the second most common cancer in men worldwide, but it is unusual among solid tumors in that many men die with, rather than of, the disease. This raises challenges in terms of deciding if, when, and how to intervene to control tumor growth and spread in order to extend survival without compromising quality of life. The many developments in the field since the last edition of this book include continuing studies to improve detection and monitoring of the disease, with the evaluation of MRI for screening and prostate-specific membrane antigen (PSMA)-PET/CT for staging. Treatment options have also continued to improve and expand for all stages of the disease with the development of ultrahypofractionated radiotherapy, oral LHRH antagonists, PARP inhibitors and lutetium-177 PSMA-617 radioligand therapy.

Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists.

An important translational book bridging the gap between science and clinical medicine, Prostate Cancer reviews the biological processes that can be implicated in the disease, reviews current treatments, highlighting the pitfalls where relevant and examines the scientific developments that might result in novel treatments in the future.Key Features* Provides a translational resource for scientists and clinicians working on prostate cancer* Reviews current surgical interventions and highlights their related pitfalls* Presents the latest laparoscopic techniques with figures and illustrations of step-by-step procedures* Offers insight into the potential for novel approaches to treatment in the future* Includes personal perspectives from patients

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.